Dehydrostobadine

Dehydrostobadine

SCHEMBL13320178

[2H]C([2H])([2H])N1CCc2[nH]c3ccc(C)cc3c2C1

nearest known ligand 0.80

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.80
SIRT2 Q8IXJ6 1/20 0.62
ACHE P22303 4/20 0.61
GRIN1 Q05586 3/20 0.61
GRIN2A Q12879 3/20 0.61
GRIN2D O15399 2/20 0.61
GRIN3B O60391 2/20 0.61
GRIN2B Q13224 2/20 0.61
GRIN2C Q14957 2/20 0.61
GRIN3A Q8TCU5 2/20 0.61
BAZ2B Q9UIF8 1/20 0.61
LMNA P02545 1/20 0.56
PABPC1 P11940 1/20 0.56
ATM Q13315 1/20 0.56
SMN1; SMN2 Q16637 1/20 0.56
ALOX15 P16050 2/20 0.55
HSD17B10 Q99714 2/20 0.55
USP2 O75604 2/20 0.55
CYP1A2 P05177 1/20 0.55
CYP2D6 P10635 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Dehydrostobadine SCHEMBL167500 0.90 L3MBTL1 (0.97) L3MBTL1SIRT2ACHEGRIN1GRIN2A
Dehydrostobadine SCHEMBL29468212 0.90 L3MBTL1 (0.97) L3MBTL1SIRT2ACHEGRIN1GRIN2A
Dehydrostobadine SCHEMBL3715610 0.89 L3MBTL1 (1.00) L3MBTL1SIRT2ACHEGRIN1GRIN2A
Dehydrostobadine SCHEMBL2837548 0.89 L3MBTL1 (1.00) L3MBTL1SIRT2ACHEGRIN1GRIN2A
SCHEMBL3238110 0.82 L3MBTL1 (0.78) L3MBTL1SIRT2ACHEGRIN1GRIN2A
SCHEMBL10127681 0.82 L3MBTL1 (0.82) L3MBTL1SIRT2ACHEGRIN1GRIN2A
SCHEMBL2186665 0.80 L3MBTL1 (0.70) L3MBTL1SIRT2ACHEGRIN1GRIN2A
SCHEMBL12868029 0.79 L3MBTL1 (0.73) L3MBTL1SIRT2ACHEGRIN1GRIN2A
SCHEMBL1120507 0.78 L3MBTL1 (0.76) L3MBTL1SIRT2ACHEGRIN1GRIN2A
SCHEMBL15977201 0.78 L3MBTL1 (0.76) L3MBTL1SIRT2ACHEGRIN1GRIN2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100125085-A1 PYRIDOINDOLE MODULATORS OF NMDA RECEPTOR AND ACETYLCHOLINESTERASE AUSPEX PHARMACEUTICALS, INC. (US) 2010-05-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100125085-A1 PYRIDOINDOLE MODULATORS OF NMDA RECEPTOR AND ACETYLCHOLINESTERASE GRIN3A, GRIK5, CHRNA5 L3MBTL1 3873/4885SIRT2 2988/4885ACHE 15/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.